semaglutide at home How to Administer Your Own Injections Semaglutide + BioBoost Injections Home

Reduced Risk of Cardiovascular Events: Semaglutide has been associated with a lower risk of cardiovascular events in patients with type 2 diabetes

Real-World Evidence: A retrospective cohort study using electronic health record data found that tirzepatide was associated with a mean weight loss of 6.6 kg compared to 3.1 kg for semaglutide over a 6-month follow-up period

Clinical trials have long been the foundation of evidence generation, but they are often slow, costly, and limited in how well they reflect real-world patient populations

Those on the GLP-1 dulaglutide were found to have a 14% risk reduction of cognitive decline compared with those on placebo

84 Survodutide Survodutide is a weekly subcutaneous GLP-1/glucagon dual agonist structurally modified from native glucagon currently in development for treatment of obesity, T2DM and MASH

Many individuals start with GLP-1 medications before considering bariatric surgery later if additional support is needed